Gilead Sciences (NASDAQ:GILD)

health care

5 Health Care Stocks That Need to Play Serious Catch Up

2014 has been another amazing year for stocks, and now the bull market is closer to being six years old and stocks have risen some 200% from the inflection bottom ...
Read Full Story »
Wall Street/NYSE

Insider Selling Surges as Markets Hit Record High

With the S&P 500 and the Dow Jones Industrial Average at record highs, and the Nasdaq hitting highs not seen since 2000, the volume of insider selling reached some of ...
Read Full Story »
biotech

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

One sad trend that has exploded in the new millennium has been the increase in hepatitis C cases in the Unites States and around the world. One startling fact is ...
Read Full Story »
462542665

Gilead Sees Large Insider Stock Sale Into Debt Offering

Gilead Sciences Inc. (NASDAQ: GILD) has become the largest biotech now. The company has run into controversy of late over the pricing of its hepatitis C drug, but it has ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific (Updated)

The short interest data are out for the October 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
health care

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Many investors want to try to find the stocks that are going to offer the traditional “beat and raise estimates” before they release quarterly earnings reports. Actually, it has always ...
Read Full Story »
Money background. Close-up.

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences Inc. (NASDAQ: GILD) reported its third-quarter results after the market close on Monday as $1.84 in earnings per share and $6.04 billion in revenue. That was against Thomson ...
Read Full Story »
biotech

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its third-quarter earnings after the U.S. markets close on Tuesday. Thomson Reuters has consensus estimates of $1.92 in earnings per shares ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

The recent market sell-off spared no sector, and the top biotechnology stocks were treated with their own trip to the woodshed. Rising trends in prescriptions and higher, yet beatable increases ...
Read Full Story »
Cisco logo

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

After a 14-year secular bear market that finally ended when the S&P 500 broke solidly above the 1,600 level in the summer of last year, prompting a move to record ...
Read Full Story »
Disney logo

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Typically midterm election years are good years for the stock market. While there is no guarantee that this year will follow the past, there is a good chance that the ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
health care

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

For a variety of reasons, the cases of chronic hepatitis in the United States have surged dramatically over the past 20 years. Currently, it is estimated that more than 3.2 ...
Read Full Story »
Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »